Brief: Newron: Zambon And Valeo Pharma Launch Onstryv For Parkinson's disease In Canada
10/07/2019 16:39
July 10 (Reuters) - Newron Pharmaceuticals SpA NWRN.S :
* DGAP-NEWS: NEWRON'S COMMERCIALIZATION PARTNER ZAMBON AND
VALEO
PHARMA ANNOUNCE THE LAUNCH OF ONSTRYV(R) (SAFINAMIDE) FOR
PARKINSON'S DISEASE IN CANADA
Source text for Eikon: ID:nEQ6gqHRma
Further company coverage: NWRN.S
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Newron Pharmaceuticals SpA
See all newsUS FDA flags four deaths in Newron's schizophrenia drug studies (updated)
US FDA cites 4 deaths in Newron's schizophrenia drug trial hold
Brief: Newron Says Topline Data From ENIGMA-TRS 1 Expected In Q1 2027
Brief: Newron Provides Update Following Type A Meeting With The FDA
Brief: Newron Reports Pause Of Enrollment Of New Study Participants In US Centers Of ENIGMA-TRS 2 Study